Showing posts with label CELLS. Show all posts
Showing posts with label CELLS. Show all posts

Friday, August 18, 2017

DIABETES FROM STEM CELLS TO INSULIN PRODUCERS




Harvard stem cell researchers announced that they have made a giant leap forward in the quest to find a truly effective treatment for type 1 diabetes, a condition that affects an estimated three million Americans at a cost of about $15 billion annually: With human embryonic stem cells as a starting point, the scientists are for the first time able to produce, in the kind of massive quantities needed for cell transplantation and pharmaceutical purposes, human insulin-producing beta cells equivalent in most every way to normally functioning beta cells.
 
Doug Melton, who led the work and who twenty-three years ago, when his then infant son Sam was diagnosed with type 1 diabetes, dedicated his career to finding a cure for the disease, said he hopes to have human transplantation trials using the cells to be underway within a few years.
"We are now just one pre-clinical step away from the finish line," said Melton, whose daughter Emma also has type 1 diabetes.
A report on the new work has been published by the journal Cell.
Felicia W. Pagliuca, Jeff Millman, and Mads Gurtler of Melton's lab are co-first authors on the Cell paper. The research group and paper authors include a Harvard undergraduate.
"You never know for sure that something like this is going to work until you've tested it numerous ways," said Melton, Harvard's Xander University Professor and a Howard Hughes Medical Institute Investigator. "We've given these cells three separate challenges with glucose in mice and they've responded appropriately; that was really exciting.
"It was gratifying to know that we could do something that we always thought was possible," he continued, "but many people felt it wouldn't work. If we had shown this was not possible, then I would have had to give up on this whole approach. Now I'm really energized."
The stem cell-derived beta cells are presently undergoing trials in animal models, including non-human primates, Melton said.
Elaine Fuchs, the Rebecca C. Lancefield Professor at Rockefeller University, and a Howard Hughes Medical Institute Investigator who is not involved in the work, hailed it as "one of the most important advances to date in the stem cell field, and I join the many people throughout the world in applauding my colleague for this remarkable achievement.
"For decades, researchers have tried to generate human pancreatic beta cells that could be cultured and passaged long term under conditions where they produce insulin. Melton and his colleagues have now overcome this hurdle and opened the door for drug discovery and transplantation therapy in diabetes," Fuchs said.
And Jose Oberholtzer, M.D., Associate Professor of Surgery, Endocrinology and Diabetes, and Bioengineering at the University of Illinois at Chicago, and its Director of the Islet and Pancreas Transplant Program and the Chief of the Division of Transplantation, said work described in today's Cell "will leave a dent in the history of diabetes. Doug Melton has put in a life-time of hard work in finding a way of generating human islet cells in vitro. He made it. This is a phenomenal accomplishment."
Melton, co-scientific director of the Harvard Stem Cell Institute, and the University's Department of Stem Cell and Regenerative Biology -- both of which were created more than a decade after he began his quest -- said that when he told his son and daughter they were surprisingly calm. "I think like all kids, they always assumed that if I said I'd do this, I'd do it," he said with a self-deprecating grin.
Type 1 diabetes is an autoimmune metabolic condition in which the body kills off all the pancreatic beta cells that produce the insulin needed for glucose regulation in the body. Thus the final pre-clinical step in the development of a treatment involves protecting from immune system attack the approximately 150 million cells that would have to be transplanted into each patient being treated. Melton is collaborating on the development of an implantation device to protect the cells with Daniel G. Anderson, the Samuel A. Goldblith Professor of Applied Biology, Associate Professor in the Department of Chemical Engineering, the Institute of Medical Engineering and Science, and the Koch Institute at MIT.
Melton said that the device Anderson and his colleagues at MIT are currently testing has thus far protected beta cells implanted in mice from immune attack for many months. "They are still producing insulin," Melton said.
Cell transplantation as a treatment for diabetes is still essentially experimental, uses cells from cadavers, requires the use of powerful immunosuppressive drugs, and has been available to only a very small number of patients.
MIT's Anderson said the new work by Melton's lab is "an incredibly important advance for diabetes. There is no question that ability to generate glucose-responsive, human beta cells through controlled differentiation of stem cells will accelerate the development of new therapeutics. In particular, this advance opens to doors to an essentially limitless supply of tissue for diabetic patients awaiting cell therapy."
Richard A. Insel, M.D., chief scientific officer of the Juvenile Diabetes Research Foundation, a funder of Melton's work, said the "JDRF is thrilled with this advancement toward large scale production of mature, functional human beta cells by Dr. Melton and his team. This significant accomplishment has the potential to serve as a cell source for islet replacement in people with type 1 diabetes and may provide a resource for discovery of beta cell therapies that promote survival or regeneration of beta cells and development of screening biomarkers to monitor beta cell health and survival to guide therapeutic strategies for all stages of the disease."
Melton expressed gratitude to both the Juvenile Diabetes Research Foundation and the Helmsley Trust, saying "their support has been, and continues to be essential."
While diabetics can keep their glucose metabolism under general control by injecting insulin multiple times a day, that does not provide the kind of exquisite fine tuning necessary to properly control metabolism, and that lack of control leads to devastating complications from blindness to loss of limbs.
About 10 percent of the more than 26 million Americans living with type 2 diabetes are also dependent upon insulin injections, and would presumably be candidates for beta cell transplants, Melton said.
"There have been previous reports of other labs deriving beta cell types from stem cells, no other group has produced mature beta cells as suitable for use in patients," he said. "The biggest hurdle has been to get to glucose sensing, insulin secreting beta cells, and that's what our group has done."


Friday, August 4, 2017

How Injured Nerve Cells Can Repair Themselves


Today's easy to read and interesting post from news-medical.net (see link below) talks about how nerve cells can and do regenerate and how certain molecules make that happen. Researchers are trying to find ways to speed up that process, with obvious benefits for neuropathy patients, especially those with axonal neuropathy where the damage can be some distance from the nerve nucleus. It's one more example of how research at a molecular level may be of great benefit in the future.


Researchers study how nerve cells repair themselves after injury
Posted in: Medical Science News | Medical Research News
Published on March 25, 2013 at 3:22 AM ·


One molecule makes nerve cells grow longer. Another one makes them grow branches. These new experimental manipulations have taken researchers a step closer to understanding how nerve cells are repaired at their farthest reaches after injury. The research was recently published in the Journal of Neuroscience.

"If you injure a peripheral nerve, it will spontaneously regenerate, but it goes very slowly. We're trying to speed that up," said Dr. Jeffery Twiss, a professor and head of the biology department at Drexel University in the College of Arts and Sciences, who was senior author of the paper.

But, Twiss said, scientists still have a lot to learn about how nerve cells repair themselves. He and his colleagues are especially interested in how nerve cells are repaired in their longest-reaching sections, their axons. Axons can be up to a meter long in adult human nerve cells, extending away from the cell body toward neighboring nerve cells, with which they exchange signals. Restoring length to damaged axons is essential to restoring nerve function, but coordinating these repairs at a great distance from the cell's nucleus involves a mix of complex processes within each cell. To gain insight into these processes, they have focused research, including the present study, on repair proteins that are created locally near an injury site in a nerve's axon.

Dr. Christopher Donnelly, now a postdoctoral fellow at Johns Hopkins University, led the study as part of his dissertation work in Twiss' lab while at the University of Delaware.

Donnelly and Twiss knew from their previous research that two of the messenger RNA(mRNA) molecules involved in directing repair in injured axons compete against each other at an essential step in repairing damage. The mRNA molecules that "win" the competition get to make their particular repair-protein product.

So, experimentally, they rigged the competition between those molecules to see what would happen. Could one molecule make a difference in helping axons grow longer, faster?

The technical process of these experiments was complex, but the answers are easy to see.

They saw more branches in the axons when they added more mRNA used to make the repair protein beta-actin, while taking away the mRNA for the protein GAP-43.

But they got the desired longer, less-branched axons from the opposite experiment, adding mRNA coding for GAP-43 and taking away that for beta-actin.

This was a promising result for developing potential therapies, Donnelly said. When nerves repair themselves after injury, there is currently no way to control their pattern of regrowth. But, "if you can induce longer growth quicker, rather than branching growth, you can help reach the target of faster recovery from an injury."

Yet other modifications, selectively withholding the mRNA molecules, resulted in shorter axons, or in fewer axon branches - and the researchers found they could experimentally and selectively restore branching or lengthening growth in those deprived cells, too. Consistent with the first experiments' results, adding more beta-actin mRNA again restored axon branching, and adding more GAP-43 mRNA again restored axon length.

But a key point in these experiments is that all of the changes only happened when they added mRNA molecules that functioned as the proteins' "local recipe" used especially for making these proteins in the nerves' axons. The "standard recipe" of mRNA, that directs cells to make those same proteins in the cell body, didn't have these distinct effects on the axons' growth.

This experimental technique to manipulate axon growth was not previously tested, the authors noted. They found most of these results using adult rat neurons in vitro, but also confirmed the principles in vivo with the developing spinal cord of chicken embryos in collaboration with Dr. Gianluca Gallo of Temple University.

"This sets some of the groundwork needed to consider using these mechanisms for improving regeneration in the future," Twiss said. This basic science research will require further testing in animals before considering any advance to humans as an eventual possibility. Drexel University has filed a patent application for the techniques used in these experiments to selectively drive translation of mRNA molecules of interest within axons.

Source: Drexel University

http://www.news-medical.net/news/20130325/Researchers-study-how-nerve-cells-repair-themselves-after-injury.aspx

Monday, July 10, 2017

SCIENTISTS GROW LEG MUSCLE FROM CELLS IN A DISH


A team of researchers from Italy, Israel and the United Kingdom has succeeded in generating mature, functional skeletal muscles in mice using a new approach for tissue engineering. The scientists grew a leg muscle starting from engineered cells cultured in a dish to produce a graft. The subsequent graft was implanted close to a normal, contracting skeletal muscle where the new muscle was nurtured and grown. In time, the method could allow for patient-specific treatments for a large number of muscle disorders.
The results are published in EMBO Molecular Medicine.
The scientists used muscle precursor cells -- mesoangioblasts -- grown in the presence of a hydrogel (support matrix) in a tissue culture dish. The cells were also genetically modified to produce a growth factor that stimulates blood vessel and nerve growth from the host. Cells engineered in this way express a protein growth factor that attracts other essential cells that give rise to the blood vessels and nerves of the host, contributing to the survival and maturation of newly formed muscle fibres. After the graft was implanted onto the surface of the skeletal muscle underneath the skin of the mouse, mature muscle fibres formed a complete and functional muscle within several weeks. Replacing a damaged muscle with the graft also resulted in a functional artificial muscle very similar to a normal Tibialis anterior.
Tissue engineering of skeletal muscle is a significant challenge but has considerable potential for the treatment of the various types of irreversible damage to muscle that occur in diseases like Duchenne muscular dystrophy. So far, attempts to re-create a functional muscle either outside or directly inside the body have been unsuccessful. In vitro-generated artificial muscles normally do not survive the transfer in vivo because the host does not create the necessary nerves and blood vessels that would support the muscle's considerable requirements for oxygen.
"The morphology and the structural organisation of the artificial organ are extremely similar to if not indistinguishable from a natural skeletal muscle," says Cesare Gargioli of the University of Rome, one of the lead authors of the study.
In future, irreversibly damaged muscles could be restored by implanting the patient's own cells within the hydrogel matrix on top of a residual muscle, adjacent to the damaged area. "While we are encouraged by the success of our work in growing a complete intact and functional mouse leg muscle we emphasize that a mouse muscle is very small and scaling up the process for patients may require significant additional work," comments EMBO Member Giulio Cossu, one of the authors of the study. The next step in the work will be to use larger animal models to test the efficacy of this approach before starting clinical studies.



Friday, June 23, 2017

HEARTS ACTION IMMUNE CELLS CAN HELP IT HEAL



The heart holds its own pool of immune cells capable of helping it heal after injury, according to new research in mice at Washington University School of Medicine in St. Louis.
Most of the time when the heart is injured, these beneficial immune cells are supplanted by immune cells from the bone marrow, which are spurred to converge in the heart and cause inflammation that leads to further damage. In both cases, these immune cells are called macrophages, whether they reside in the heart or arrive from the bone marrow. Although they share a name, where they originate appears to determine whether they are helpful are harmful to an injured heart.
In a mouse model of heart failure, the researchers showed that blocking the bone marrow's macrophages from entering the heart protects the organ's beneficial pool of macrophages, allowing them to remain in the heart, where they promote regeneration and recovery. The findings may have implications for treating heart failure in humans.
The study is now available in The Proceedings of the National Academy of Sciences Early Edition.
"Researchers have known for a long time that the neonatal mouse heart can recover well from injury, and in some cases can even regenerate," said first author Kory J. Lavine, MD, PhD, instructor in medicine. "If you cut off the lower tip of the neonatal mouse heart, it can grow back. But if you do the same thing to an adult mouse heart, it forms scar tissue."
This disparity in healing capacity was long a mystery because the same immune cells appeared responsible for both repair and damage. Until recently, it was impossible to distinguish the helpful macrophages that reside in the heart from the harmful ones that arrive from the bone marrow.
The new research and past work by the same group -- led by Douglas L. Mann, MD, the Tobias and Hortense Lewin Professor of Medicine and cardiologist-in-chief at Barnes-Jewish Hospital -- appear to implicate these immune cells of different origins as responsible for the difference in healing capacity seen in neonatal and adult hearts, at least in mice.
"The same macrophages that promote healing after injury in the neonatal heart also are present in the adult heart, but they seem to go away with injury," Lavine said. "This may explain why the young heart can recover while the adult heart can't."
Because they are interested in human heart failure, Lavine and his colleagues developed a method to progressively damage mouse cardiac tissue in a way that mimicked heart failure. They compared the immune response to cardiac damage in neonatal and adult mouse hearts.
The investigators found that the helpful macrophages originate in the embryonic heart and harmful macrophages originate in the bone marrow and could be distinguished by whether they express a protein on their surface called CCR2. Macrophages without CCR2 originate in the heart; those with CCR2 come from the bone marrow, the research showed.
Lavine and his colleagues asked whether a compound that inhibits the CCR2 protein would block the bone marrow's macrophages from entering the heart.
"When we did that, we found that the macrophages from the bone marrow did not come in," Lavine said. "And the macrophages native to the heart remained. We saw reduced inflammation in these injured adult hearts, less oxidative damage and improved repair. We also saw new blood vessel growth. By blocking the CCR2 signaling, we were able to keep the resident macrophages around and promote repair."


Monday, May 29, 2017

ACTIVATING HAIR GROWTH BY MODIFYING IMMUNE CELLS


How to restore hair loss is a task not undertaken exclusively by beauty practitioners. The discovery, now published by a group from the Spanish National Cancer Research Centre (CNIO), reveals a novel angle to spur hair follicle growth. This also adds new knowledge to a broader problem: how to regenerate tissues in an adult organism, especially the skin.

 The group has discovered an unexpected connection--a link between the body's defense system and skin regeneration. According to the authors of the study published today in PLOS Biology, cells from the immune system called macrophages-- those in charge of devouring invading pathogens, for example--are also responsible for activating skin stem cells and induce hair growth.
The regenerative ability of stem cells allows skin replenishment during a lifetime. But different factors can reduce their regenerative properties or promote their uncontrolled growth. When things go wrong, this can lead to aging and disease, including skin carcinomas. The discovery that macrophages activate skin stem cells may also have further implications beyond the possibility to develop therapeutic approaches for hair loss, but may also be relevant for cancer research.
The authors of the study are Mirna Perez-Moreno and Donatello Castellana, from the Epithelial Cell Biology Group of the BBVA Foundation-CNIO Cancer Cell Biology Programme, along with Ralf Paus, a hair immunobiology expert from the University of Manchester and Münster.
"We have discovered that macrophages, cells whose main function is traditionally attributed to fight infections and wound repair, are also involved in the activation of hair follicle stem cells in non inflamed skin," says Perez-Moreno.
The researchers did not investigate the relationship between macrophages and hair for fun. This work emerged more than four years ago from an observation made by Perez-Moreno while working on another research project. The mice she had been working with at that time received anti-inflammatory drugs, a treatment that also reactivated hair growth. Convinced that the explanation could reside in the existence of close communication between stem cells and immune cells --the Perez-Moreno's lab began to experiment with the different types of cells involved in the body´s defense system.
After years of investigation, they discovered that when stem cells are dormant, a fraction of macrophages die, due to a process known as apoptosis. This stimulated the secretion of factors from dying and living macrophages, which in turn activated stem cells, and that is when hairs began to grow again.
Reproducing natural process
Macrophages secrete a number of factors including a class of proteins called Wnt.
Researchers demonstrated the participation of macrophage-derived Wnts by artificially reproducing the natural process by treating macrophages with a Wnt inhibitor drug encapsulated in liposomes. As expected, when they used this drug, the activation of hair growth was delayed.
Although this study has been completed in mice, the researchers believe their discovery "may facilitate the development of novel treatment strategies" for hair growth in humans.
The possibility of attacking one type of cell to affect another might have broader applications that go beyond "just" growing hair. Furthermore, the use of liposomes as a way of drug delivery to specific cells, is a very promising line of experimentation, which may have implications for the study of several pathologies, says Donatello Castellana.
From a more fundamental perspective, this research is an effort to understand how modifying the environment that surrounds adult skin stem cells can regulate their regenerative capabilities. "One of the current challenges in the stem cell field is to regulate the activation of endogenous stem cell pools in adult tissues to promote regeneration without the need of transplantation," says Perez-Moreno.
Biochemical dialogue
It is now known that macrophages are key cells involved in the biochemical dialogue that exists in the environment surrounding stem cells.
"Our study underlines the importance of macrophages as modulators in skin regenerative processes, going beyond their primary function as phagocytes [immune system cells]," say the authors in PLoS Biology.
The researcher´s next goal is to characterise the class of macrophage(s) that are involved in the activation of skin stem cells and their implications in the regulation of stem cells under pathological conditions, including skin carcinomas.
As Perez-Moreno explains, "macrophages are a very diverse cell population. It was only less that ten years ago that scientists discovered that besides from the bone marrow, macrophages originate from the yolk sac during pregnancy, and there are even other macrophages that proliferate within tissues. The diversity of the sources from which skin resident macrophages originate is not fully understood."


Friday, May 19, 2017

CANCER CELLS ADAPT ENERGY NEEDS TO SPREAD ILLNESS TO OTHER ORGANS



Want to understand why cancer cells metastasize? Think of Sparta.

Ancient Greek warriors were fed a special diet that better prepared them for the demands of battle on distant fields. Cancer cells that metastasize may do the same thing according to a new study revealing previously unknown differences between cancer cells that continue to grow at the original tumor site, and those that travel to other organs.
Given that a cancer cell's unyielding ability to metastasize is the primary cause of cancer-related death, understanding how they successfully migrate can be lifesaving.
Scientists at The University of Texas MD Anderson Cancer Center have found that cancer cells traveling to other sites have different energy needs from their "stay-at-home" siblings which continue to proliferate at the original tumor site. The study results are in the Sept. 21 online edition of Nature Cell Biology.
The reason may lie with the protein, PGC-1α, a type of transcription co-activator crucial to regulation of cellular metabolism. PGC-1α appears to play a role in how cancer cells are able to acquire unique energy sources that allow them to travel and spread cancer in the body.
"New therapy strategies are beginning to focus on the unique vulnerabilities of cancer cell metabolism. Determining the metabolic requirements of invasive cancer cells could be of therapeutic value," said Valerie LeBleu, Ph.D., assistant professor of cancer biology at MD Anderson and lead author of the Nature Cell Biology paper. "We found that invading cancer cells rely on mitochondria during their transition to other cancer sites."
Cancer cells use PGC-1α to stimulate the growth of new mitochondria, the cell's "power plants" that generate ATP, an energy "currency" used by cells to grow. Metastasizing cells also rely on PGC-1α for a process known as oxidative phosphorylation that boosts ATP during the cell's journey to other sites. If mitochondria is the kitchen, then PGC-1α is the chef, ATP the entreé and oxidative phosphorylation a key ingredient. This overall process, mitochondria respiration, allows some cancer cells to harness the required energy to survive the hostile journey through tumor and normal issue, blood vessels, and entry into new organs.
In other words, some cancer cells are programmed to eat at home, while others have a special diet that allows them to travel to other sites. If there was a therapeutic way to stop the migrating cells from packing a lunch ahead of time, it could potentially halt their journey. Suppressing PGC-1α appears to accomplish this.
"The most dangerous cancer cells are the ones that can efficiently move and find a new home," said Raghu Kalluri, M.D., Ph.D., chair of cancer biology and an investigator on the study. "The study revealed a strong correlation between PGC-1α expression in invasive cancer cells and the formation of distant metastases in breast cancer patients."




Saturday, May 6, 2017

Pain Cells In A Dish Lead To Better Pain Medication


Today's post from vector.childrenshospital.org (see link below) is already a year old and we can expect that further advances will have been made but it introduces the idea of genetically creating nociceptors (pain-sensing nerve cells) in a dish, in a lab. The idea being that, pain-killing drugs can be tested safely without needing animal or human models. Furthermore, these nociceptors will be created so that there are far less variables than in animal test subjects, thus creating more certainty, more speed and quicker development of future drugs. This sort of stem cell research is a huge breakthrough and chronic nerve pain patients will certainly benefit from new medications in the years to come because the research is so much easier and much more specific. It's a short article and easy to follow - worth a read.

Modeling pain in a dish: Nociceptors made from skin recreate pain physiology
Posted on December 12, 2014 by Nancy Fliesler

Chronic pain, affecting tens of millions of Americans alone, is debilitating and demoralizing. It has many causes, and in the worst cases, people become “hypersensitized”—their nervous systems fire off pain signals in response to very minor triggers.

There are no good medications to calm these signals, in part because the subjectivity of pain makes it difficult to study, and in part because there haven’t been good research models. Drugs have been tested in animal models and “off the shelf” cell lines, some of them engineered to carry target molecules (such as the ion channels that trigger pain signals). Drug candidates emerging from these studies initially looked promising but haven’t panned out in clinical testing.

“These models don’t tell you what the drug is doing to the whole functioning neuron,” says Elizabeth Buttermore, PhD, a postdoctoral fellow in the F.M. Kirby Neurobiology Center at Boston Children’s Hospital. “They haven’t been holding up.”

Last month in Nature Neuroscience, Buttermore coauthored a report with Brian Wainger, MD, of Boston Children’s and Massachusetts General Hospital, describing a new model that appears to capture pain physiology in a dish, using skin cells as their raw material. Their model, also a technical breakthrough in stem cell research, offers new opportunities to understand how pain is produced and to discover new analgesics.


A nimbler way to make neurons

Labs all over the world are beginning to reprogram skin cells into cells resembling embryonic stem cells, known as induced pluripotent stem (iPS) cells, and transforming those, in turn, to their cell type of choice. But Buttermore, Wainger and colleagues found that they were able to bypass the somewhat cumbersome step of creating iPS cells.

By adding just five signals (namely, transcription factors) to skin cells from mice and from patients with an inherited pain disorder, they were able to create nociceptors—specialized pain-sensing neurons. Two of these signals hadn’t been known before and were found by examining mature nociceptors from mice.

In tests, the lab-created mouse nociceptors closely resembled “natural” neurons. They functioned, responded to different pain triggers and became hypersensitized to pain just like their real-world counterparts. The lab-created human nociceptors still have some hoops to jump through, but by early measures, they appear to “beautifully model” patients’ neuropathies and pain hypersensitivities, says Clifford Woolf, MB, BCh, PhD, senior investigator on the project and director of the Kirby Center.

The nociceptor model is already revealing new aspects of pain physiology and could ultimately provide a much more realistic platform for testing new drugs. Woolf, who also co-leads the Harvard Stem Cell Institute’s Nervous System Diseases Program has already found this to be true for amyotrophic lateral sclerosis (ALS).

The nociceptor project’s success was a long time in coming. The team had first tried to make nociceptors from embryonic stem cells. “We spent three years trying to recapitulate the developmental steps involved, and it turned out to be a total bust,” said Woolf.

But he refused to pull the plug, and the approach that finally worked turns out to be the most expedient and the most clinically relevant: Skin cells can be collected directly from patients, making it easier to model their different kinds of chronic pain—neuropathies caused by genetic mutations, diabetes or even chemotherapy, which can sensitize patients to pain.

“We’re trying to get to clinical trials with more success,” says Buttermore. “Hopefully, we’ll avoid drugs that don’t work.”

http://vector.childrenshospital.org/2014/12/modeling-pain-in-a-dish-nociceptors-made-from-skin-recreate-pain-physiology/

Friday, April 21, 2017

Cells Causing Neuropathic Pain Identified



Today's post comes from news-medical.net (see link below). It talks about the fact that new research has identified the particular sensory nerve cells that bring about long-term neuropathic pain. This is important because in the future, drugs can be developed to target the problem much more effectively. Let's hope it's not too far in the future!


Chronic nerve pain: researchers identify which sensory nerve cells are responsible
Published on August 13, 2012

New research, led by academics at the University of Bristol and published in the journal Pain, has identified the subtypes of sensory nerve cells that are likely to contribute to long-term nerve pain from partial nerve injury. It is hoped this will aid in development of more effective pain killers.

Partial nerve injury can be caused by an accident, diseases such as diabetes or result from surgery. Essentially, it results in a) death and degeneration of some nerve fibres which causes inflammation within the nerve, but b) survival of other fibres that continue to conduct through the damaged and/or inflamed nerve.

This combination can result in serious long-term neuropathic pain. This neuropathic pain has various different qualities. The most debilitating is the often relentless spontaneous ongoing burning or sharp shooting pain. In addition, there may be greater pain than usual in response to normally painful stimuli, as well as extreme tenderness and pain to normal touch or in response to normal movements.

There may also be strange, often unpleasant, but non-painful sensations. Neuropathic pain remains very hard to treat clinically. The reasons include incomplete understanding of the types of nerve cells responsible for these different qualities of pain.

Sensory nerve cells have nerve fibres that carry the signals from the tissues, such as skin, muscle and organs, to the central nervous system (CNS). Some are nociceptors or “pain nerve cells”. They sense and signal tissue damage or inflammation; their signals activate pain pathways to the brain, which results in pain. Other types of neurons when activated cause non-painful sensations, such as touch, vibration etc.

The researchers report profound changes in properties of different subpopulations of the sensory nerve cells with surviving uninjured fibres; these are the focus of their publication in the journal Pain. They observed changes that could account for the different qualities of neuropathic pain as follows.
They found spontaneous ongoing firing in different groups of pain nerve cells which would cause ongoing burning and sharp shooting pain; they report spontaneous firing in non-pain nerve cells that could cause the abnormal non painful sensations; they also show increased sensitivity of fast conducting nociceptors which could underlie the increased pain resulting from stimulation of the tissues.

Professor Sally Lawson, Emeritus Professor from the University’s School of Physiology and Pharmacology who led the research at Bristol, said: “We hope that our findings will trigger further studies that will clarify how and why these nerve cells with uninjured fibres running through a damaged nerve change so remarkably and contribute to pathological pain, and determine how to reverse these changes.”

Dr Laiche Djouhri, the first author, now at Liverpool (Department of Molecular and Clinical Pharmacology), added: “This should help the understanding of how to target pathological pain more effectively, taking into account the different neuron types involved. This may in the longer term help development of more effective pain killers to help sufferers of neuropathic pain.”

The Wellcome Trust-funded research, entitled ‘Partial nerve injury induces electrophysiological changes in conducting (uninjured) nociceptive and nonnociceptive DRG neurons: Possible relationships to aspects of peripheral neuropathic pain and paresthesias’ by Laiche Djouhri , Xin Fang, Stella Koutsikou, Sally N. Lawson from the School of Physiology and Pharmacology at the University of Bristol, is published in the September issue of the journal Pain.

Source: www.bris.ac.uk

http://www.news-medical.net/news/20120813/Chronic-nerve-pain-researchers-identify-which-sensory-nerve-cells-are-responsible.aspx?page=2

Saturday, April 8, 2017

ON OFF SWITCH FOR AGING CELLS DISCOVERED BY SCIENTISTS



Scientists at the Salk Institute have discovered an on-and-off “switch” in cells that may hold the key to healthy aging. This switch points to a way to encourage healthy cells to keep dividing and generating, for example, new lung or liver tissue, even in old age.

In our bodies, newly divided cells constantly replenish lungs, skin, liver and other organs. However, most human cells cannot divide indefinitely–with each division, a cellular timekeeper at the ends of chromosomes shortens. When this timekeeper, called a telomere, becomes too short, cells can no longer divide, causing organs and tissues to degenerate, as often happens in old age. But there is a way around this countdown: some cells produce an enzyme called telomerase, which rebuilds telomeres and allows cells to divide indefinitely.
In a new study published September 19 in the journalGenes and Development, scientists at the Salk Institute have discovered that telomerase, even when present, can be turned off.
“Previous studies had suggested that once assembled, telomerase is available whenever it is needed,” says senior author Vicki Lundblad, professor and holder of Salk’s Ralph S. and Becky O'Connor Chair. “We were surprised to discover instead that telomerase has what is in essence an ‘off’ switch, whereby it disassembles.”
Understanding how this “off” switch can be manipulated–thereby slowing down the telomere shortening process–could lead to treatments for diseases of aging (for example, regenerating vital organs later in life).
Lundblad and first author and graduate student Timothy Tucey conducted their studies in the yeast Saccharomyces cerevisiae, the same yeast used to make wine and bread. Previously, Lundblad’s group used this simple single-celled organism to reveal numerous insights about telomerase and lay the groundwork for guiding similar findings in human cells.
“We wanted to be able to study each component of the telomerase complex but that turned out to not be a simple task,” Tucey said. Tucey developed a strategy that allowed him to observe each component during cell growth and division at very high resolution, leading to an unanticipated set of discoveries into how–and when–this telomere-dedicated machine puts itself together.
Every time a cell divides, its entire genome must be duplicated. While this duplication is going on, Tucey discovered that telomerase sits poised as a “preassembly” complex, missing a critical molecular subunit. But when the genome has been fully duplicated, the missing subunit joins its companions to form a complete, fully active telomerase complex, at which point telomerase can replenish the ends of eroding chromosomes and ensure robust cell division.
Surprisingly, however, Tucey and Lundblad showed that immediately after the full telomerase complex has been assembled, it rapidly disassembles to form an inactive “disassembly” complex — essentially flipping the switch into the “off” position. They speculate that this disassembly pathway may provide a means of keeping telomerase at exceptionally low levels inside the cell. Although eroding telomeres in normal cells can contribute to the aging process, cancer cells, in contrast, rely on elevated telomerase levels to ensure unregulated cell growth. The “off” switch discovered by Tucey and Lundblad may help keep telomerase activity below this threshold.